APA (7th ed.) Citation

Huang, C., Lin, C., Su, T., Yang, C., Tsai, T., Hsu, C., . . . Yu, C. (2023). Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC cancer, 23(1), 234-10. https://doi.org/10.1186/s12885-023-10698-5

Chicago Style (17th ed.) Citation

Huang, Chun-Ta, et al. "Monitoring of T790M in Plasma CtDNA of Advanced EGFR-mutant NSCLC Patients on First- or Second-generation Tyrosine Kinase Inhibitors." BMC Cancer 23, no. 1 (2023): 234-10. https://doi.org/10.1186/s12885-023-10698-5.

MLA (9th ed.) Citation

Huang, Chun-Ta, et al. "Monitoring of T790M in Plasma CtDNA of Advanced EGFR-mutant NSCLC Patients on First- or Second-generation Tyrosine Kinase Inhibitors." BMC Cancer, vol. 23, no. 1, 2023, pp. 234-10, https://doi.org/10.1186/s12885-023-10698-5.